News & AnalysisBiomedicine

A Texas Wrangle Over Cancer Research Funds

See allHide authors and affiliations

Science  18 May 2012:
Vol. 336, Issue 6083, pp. 789-790
DOI: 10.1126/science.336.6083.789

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


On the way to becoming a world-class funding resource, Texas's 3-year-old, $3 billion cancer research agency has run into management troubles. Last week, Alfred Gilman, the Nobel Prize–winning biochemist who serves as the chief scientific officer of the Cancer Prevention and Research Institute of Texas announced he is stepping down this fall because he believes CPRIT's leaders are making research funding decisions that bypass scientific review. Gilman's concerns have rattled CPRIT's board members. They are now scrambling to reassure reviewers and the public—including Texas lawmakers who voted to fund CPRIT—that they remain committed to peer-reviewed science.